171 related articles for article (PubMed ID: 38424555)
21. Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations.
Jemal A; Fedewa SA; Ma J; Siegel R; Lin CC; Brawley O; Ward EM
JAMA; 2015 Nov; 314(19):2054-61. PubMed ID: 26575061
[TBL] [Abstract][Full Text] [Related]
22. Prospective study of cancer detection in black and white men with normal digital rectal examination but prostate specific antigen equal or greater than 4.0 ng/mL.
Fowler JE; Bigler SA; Farabaugh PB
Cancer; 2002 Mar; 94(6):1661-7. PubMed ID: 11920526
[TBL] [Abstract][Full Text] [Related]
23. Clinical presentation and initial management of black men and white men with prostate cancer in the United Kingdom: the PROCESS cohort study.
Evans S; Metcalfe C; Patel B; Ibrahim F; Anson K; Chinegwundoh F; Corbishley C; Gillatt D; Kirby R; Muir G; Nargund V; Popert R; Wilson P; Persad R; Ben-Shlomo Y
Br J Cancer; 2010 Jan; 102(2):249-54. PubMed ID: 19935788
[TBL] [Abstract][Full Text] [Related]
24. Use of lower prostate specific antigen cutoffs for prostate cancer screening in black and white men.
Smith DS; Carvalhal GF; Mager DE; Bullock AD; Catalona WJ
J Urol; 1998 Nov; 160(5):1734-8. PubMed ID: 9783942
[TBL] [Abstract][Full Text] [Related]
25. A prospective study of the serum prostate specific antigen concentrations and Gleason histologic scores of black and white men with prostate carcinoma.
Fowler JE; Bigler SA
Cancer; 1999 Sep; 86(5):836-41. PubMed ID: 10463983
[TBL] [Abstract][Full Text] [Related]
26. Prostate cancer incidence, stage at diagnosis, treatment and survival in ethnic groups in South-East England.
Jack RH; Davies EA; Møller H
BJU Int; 2010 May; 105(9):1226-30. PubMed ID: 19878505
[TBL] [Abstract][Full Text] [Related]
27. Prostate-specific antigen testing in inner London general practices: are those at higher risk most likely to get tested?
Nderitu P; Van Hemelrijck M; Ashworth M; Mathur R; Hull S; Dudek A; Chowdhury S
BMJ Open; 2016 Jul; 6(7):e011356. PubMed ID: 27406644
[TBL] [Abstract][Full Text] [Related]
28. Population-based prostate-specific antigen testing in the UK leads to a stage migration of prostate cancer.
Moore AL; Dimitropoulou P; Lane A; Powell PH; Greenberg DC; Brown CH; Donovan JL; Hamdy FC; Martin RM; Neal DE
BJU Int; 2009 Dec; 104(11):1592-8. PubMed ID: 19549125
[TBL] [Abstract][Full Text] [Related]
29. Prostate carcinoma among men with human immunodeficiency virus infection.
Crum NF; Spencer CR; Amling CL
Cancer; 2004 Jul; 101(2):294-9. PubMed ID: 15241826
[TBL] [Abstract][Full Text] [Related]
30. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
[TBL] [Abstract][Full Text] [Related]
31. Is prostate cancer stage migration continuing for black men in the PSA era?
Dobbs RW; Greenwald DT; Wadhwa H; Freeman VL; Abern MR
Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):210-215. PubMed ID: 28094251
[TBL] [Abstract][Full Text] [Related]
32. Trends in prostate cancer mortality among black men and white men in the United States.
Chu KC; Tarone RE; Freeman HP
Cancer; 2003 Mar; 97(6):1507-16. PubMed ID: 12627516
[TBL] [Abstract][Full Text] [Related]
33. Predictors of repeated PSA testing among black and white men from the Maryland Cancer Survey, 2006.
Zhu Y; Sorkin JD; Dwyer D; Groves C; Steinberger EK
Prev Chronic Dis; 2011 Sep; 8(5):A114. PubMed ID: 21843417
[TBL] [Abstract][Full Text] [Related]
34. Prostate-specific antigen testing rates and referral patterns from general practice data in England.
Moss S; Melia J; Sutton J; Mathews C; Kirby M
Int J Clin Pract; 2016 Apr; 70(4):312-8. PubMed ID: 26987766
[TBL] [Abstract][Full Text] [Related]
35. Testis and prostate cancer incidence in ethnic groups in South East England.
Jack RH; Davies EA; Møller H
Int J Androl; 2007 Aug; 30(4):215-20; discussion 220-1. PubMed ID: 17573844
[TBL] [Abstract][Full Text] [Related]
36. Total, free, and percent free prostate-specific antigen levels among U.S. men, 2001-04.
Lacher DA; Thompson TD; Hughes JP; Saraiya M
Adv Data; 2006 Dec; (379):1-12. PubMed ID: 17348177
[TBL] [Abstract][Full Text] [Related]
37. Use of the prostate-specific antigen test among U.S. men: findings from the 2005 National Health Interview Survey.
Ross LE; Berkowitz Z; Ekwueme DU
Cancer Epidemiol Biomarkers Prev; 2008 Mar; 17(3):636-44. PubMed ID: 18349281
[TBL] [Abstract][Full Text] [Related]
38. Prostate-specific antigen testing rates remain low in UK general practice: a cross-sectional study in six English cities.
Williams N; Hughes LJ; Turner EL; Donovan JL; Hamdy FC; Neal DE; Martin RM; Metcalfe C
BJU Int; 2011 Nov; 108(9):1402-8. PubMed ID: 21481132
[TBL] [Abstract][Full Text] [Related]
39. Time Trends and Variation in the Use of Active Surveillance for Management of Low-risk Prostate Cancer in the US.
Cooperberg MR; Meeks W; Fang R; Gaylis FD; Catalona WJ; Makarov DV
JAMA Netw Open; 2023 Mar; 6(3):e231439. PubMed ID: 36862409
[TBL] [Abstract][Full Text] [Related]
40. Percent free prostate specific antigen and cancer detection in black and white men with total prostate specific antigen 2.5 to 9.9 ng./ml.
Fowler JE; Sanders J; Bigler SA; Rigdon J; Kilambi NK; Land SA
J Urol; 2000 May; 163(5):1467-70. PubMed ID: 10751859
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
